Unum Therapeutics has listed on the Nasdaq Global Select Market, providing exits to Novo, Sanofi, EMS and Seattle Genetics.
Unum Therapeutics, a US-based immunotherapy developer backed by pharmaceutical firms Novo, Sanofi, EMS and Seattle Genetics, has raised almost $69.3m in its initial public offering on the Nasdaq Global Select Market.
The company had priced approximately 5.8 million shares at $12 each, granting underwriters a 30-day option to purchase an additional 865,500 shares. If the option is fully exercised, proceeds could increase by almost $10.4m, bringing the total to approximately $79.7m.
Seattle Genetics has separately agreed to purchase $5m of…
